ICG Fluorescence Imaging in Trauma Patients

  • STATUS
    Recruiting
  • End date
    Jan 31, 2026
  • participants needed
    358
  • sponsor
    Dartmouth-Hitchcock Medical Center
Updated on 21 August 2021

Summary

This will be a prospective observational trial to better understand the range and variation associated with bone/soft tissue perfusion in fracture patients and examine the relationship between perfusion, measured using quantitative Indocyanine green (ICG) fluorescence and complications such as surgical site infection (SSI), persistent SSI, and fracture nonunion.

Description

This will be a prospective observational trial to better understand the range and variation associated with bone/soft tissue perfusion in fracture patients and examine the relationship between perfusion, measured using quantitative Indocyanine green (ICG) fluorescence and complications such as surgical site infection (SSI), persistent SSI, and fracture nonunion. Primary outcome measure is complication (either infection, recurrent infection or nonunion). Eligible consenting patients will receive standard of care treatment for their fracture or infection including irrigation and debridement of their operative site and/or fracture fixation. After exposure, 0.1 mg/Kg ICG will be injected intravenously and video rate ICG fluorescence images will be acquired 20 seconds before and 4 minutes after the injection, each before and after debridement. A subset of 38 post-fracture complication patients will undergo surgical treatment for their infection in Center of Innovation Surgery (CIS) and have either an intraoperative Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) after exposure but before the ICG injection or a preoperative DCE-MRI. Patients receiving surgery in the CIS will be required to sign an additional CIS-specific consent document. The need for repeat surgical procedure will be left up to the treating surgeon. If repeat procedure is needed, pre- and post-debridement quantitative ICG fluorescence images will be obtained at each procedure. Study participants will be followed at 2 weeks, 6 weeks, 3 months and 6 months from their index study surgery. Complication including index infection, recurrent infection or delaying union/nonunion will be identified at the time of diagnosis and/or during each participants assessment that occurs during routine outpatient clinic visit. Detailed information on the infection including date of diagnosis, participant signs and symptoms, culture test results, method of treatment(s), and date of resolution will be documented.

4/23/2020: Study recruitment temporarily halted due to COVID-19

Details
Condition Trauma Injury, Injury Trauma
Treatment Immunofluorescence Imaging
Clinical Study IdentifierNCT04245111
SponsorDartmouth-Hitchcock Medical Center
Last Modified on21 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Open Fracture Cohort (Cohort 1)
Patients 18 years of age or older
Open extremity fracture
Planned definitive fracture management with external fixation, internal fixation, or joint fusion
Open fracture wound management that includes formal surgical debridement within 72 hours of their injury
Will have all planned fracture care surgeries performed by a participating surgeon or delegate
Provision of informed consent
Established SSI Fracture Cohort (Cohort 2)
Patients 18 years of age or older
Extremity fracture
Prior definitive fracture management with external fixation, internal fixation, or joint fusion
Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management
Will have all fracture care surgeries performed by a participating surgeon or delegate
Provision of informed consent
Closed Fracture Cohort (Cohort 3)
Patients 18 years of age or older
Closed extremity fracture
Planned definitive fracture management with external fixation, internal fixation, or joint fusion
Will have all planned fracture care surgeries performed by a participating surgeon or delegate
Provision of informed consent

Exclusion Criteria

Open Fracture Cohort (Cohort 1)
Fracture of the hand
Iodine allergy
Received previous surgical debridement or management of their fracture at a non-participating hospital or clinic
Open fracture managed outside of the participating orthopaedic service
Chronic or acute infection at or near the fracture site at the time of initial fracture surgery
Burns at the fracture site
Incarceration
Expected survival of less than 90 days
Problems, in the judgment of study personnel, with maintaining follow-up with the patient
Established SSI Fracture Cohort (Cohort 2)
Fracture of the hand
Iodine allergy
Received previous surgical debridement to manage the SSI
Incarceration
Problems, in the judgment of study personnel, with maintaining follow-up with the patient
Subset: DCE-MRI (Cohort 2-1)
\. the presence of an electronic implant, such as a pacemaker
\. the presence of a metal implant, such as an aneurysm clip
\. the presence of other contraindication(s), as determined by the MRI
technologists and radiologists
\. A history of allergy to iodides
\. A GFR < 30 ml/min as determined by blood test on the day of NIR/MR
imaging, or from lab results within 3 months of DCE-MRI for this study
Closed Fracture Cohort (Cohort 3)
Fracture of the hand
Iodine allergy
Chronic or acute infection at or near the fracture site at the time of initial fracture surgery
Burns at the fracture site
Incarceration
Expected survival of less than 90 days
Problems, in the judgment of study personnel, with maintaining follow-up with the patient
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note